Chemically and Biologically Engineered Bacteria‐Based Delivery Systems for Emerging Diagnosis and Advanced Therapy

Abstract

Bacteria are one of the main groups of organisms, which dynamically and closely participate in human health and disease development. With the integration of chemical biotechnology, bacteria have been utilized as an emerging delivery system for various biomedical applications. Given the unique features of bacteria such as their intrinsic biocompatibility and motility, bacteria‐based delivery systems have drawn wide interest in the diagnosis and treatment of various diseases, including cancer, infectious diseases, kidney failure, and hyperammonemia. Notably, at the interface of chemical biotechnology and bacteria, many research opportunities have been initiated, opening a promising frontier in biomedical application. Herein, the current synergy of chemical biotechnology and bacteria, the design principles for bacteria‐based delivery systems, the microbial modulation, and the clinical translation are reviewed, with a special focus on the emerging advances in diagnosis and therapy.

Bacteria-driven hypoxia targeting delivery of chemotherapeutic drug proving outcome of breast cancer

“…Engineered bacteria or cells as drug delivery carriers are playing a more and more important role in the diagnosis and treatment of malignant tumors [ 50 , 51 ]. This study combines anaerobic bacteria with nanotechnology to construct a bacteria/nanoparticles biohybrids for delivery of chemotherapeutic agent.…”

Bacterial Ghosts-Based Vaccine and Drug Delivery Systems

“…They have been progressively adopted in the delivery of nucleic acids, proteins, and chemical drugs [17]. BGs are applied in several disciplines including biology, chemistry, pharmacy, biomedicine, and material sciences, among others [18]. In this paper, we reviewed the methods for BG preparation and how they induce immunity in hosts.…”

Bacterial extracellular vesicles as bioactive nanocarriers for drug delivery: Advances and perspectives

“…Although attenuated bacteria with the deletion of virulence genes improve the safety of bacteria-based delivery systems, the potential and unknown side effects remain a significant issue [ 9 ]. Recently, with the in-depth understanding of bacteria-based drug delivery systems, the use of bacterial extracellular vesicles (BEVs) for biomedical applications has become a new trend [ 10 ].…”